A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008 Oct 15; 14(20):6697-703.